CURE Pharma gets USDEA nod to develop cannabinoid-based products

CURE Pharmaceutical, an innovative drug delivery and development company, has secured a new registration with the Drug Enforcement Administration (DEA) as a manufacturer authorized to handle Schedule 1 controlled substances. With this license, CURE will develop and manufacture cannabinoid-based pharmaceutical products using its CUREfilm™ technology at its facility in Oxnard, Calif.

“This license enables CURE to translate the research findings from our collaboration with Technion – Israel Institute of Technology into potential treatments and expand our marketable product lines,” said Jessica Rousset, Chief Operating Officer of CURE Pharmaceutical. “Building upon our recent licensing agreement with Canopy Growth, CURE is now in

...read more at https://www.biospectrumasia.com/news/25/12177/cure-pharma-gets-usdea-nod-to-develop-cannabinoid-based-products.html

by

Leave a Reply